LEFTY2’s ability to inhibit TGF-β-induced Smad3 phosphorylation offers a potential strategy to modulate the effects of TGF-β in Alzheimer’s disease. Here, LEFTY2 is linked to early-onset autosomal dominant Alzheimer disease.